



2020 Joint Annual Scientific Meeting of HBPRCA, AAS and AVBS

Invitation

1 - 4 December 2020
RACV Club, Melbourne VIC

YOUR
secretariat

**3/10 Pioneer Avenue
Tuggerah, NSW 2261**

Phone 02 4356 0007

Fax 02 4355 4347

Email natasha@yoursecretariat.com.au

Welcome

In 2020, our three organisations will again join together to bring you your Annual Scientific Meeting. Based upon feedback from our members, the coming together of like-minded groups of clinicians and researchers provides a superior conference experience, higher levels of education and excellent networking opportunities for all delegates. This year the program is bigger than ever with a dedicated Young Investigator (YI) / Early Career Researcher (ECR) symposium which also incorporates the highly successful SCOLAR program, which the AAS have been running for many years. This symposium will cover many topics and attendees will have the opportunity to network together in their own afternoon tea session.

Coupled with an impressive lineup of invited guest speakers, both international visitors and home-grown experts, and generous awards for students and YI / ECRs, to be awarded at the Conference awards dinner, this joint meeting is sure to surpass previous successes.

With special thanks to all the program managers below, for putting together this impressive program, we look forward to seeing you in Melbourne for what promises to be a most excellent week.

Markus Schlaich - **President HBPRCA**

Peter Psaltis - **President AAS**

Natasha Harvey- **President AVBS**

Program Managers:

HBPRCA - Francine Marques & Bradley Broughton

AAS - Joanne Tan & Blake Cochran

AVBS - Connie Wong & Hang Ta

WHO WE ARE



The High Blood Pressure Research Council of Australia (HBPRCA) has been at the forefront of research into the causes, prevention and treatment of high blood pressure since its inception in 1979. Our research incorporates the full range from experimental molecular biology and genetics to human physiology and drug treatment of hypertension.

Our >200 members are among the national and international leaders in the field of cardiovascular research, through clinical trials, research projects, journal editorships, various academic, government and commercial committees and as active organisers and participants at major conferences.

We are the peak body for Australian scientists and clinicians studying high blood pressure and the high point of the Council's professional calendar is the Annual Scientific Meeting.

<http://www.hbprca.com.au>



The Australian Atherosclerosis Society (AAS) is the premier national society for science, research and education in the field of atherosclerosis. The Australian Atherosclerosis Society (AAS) is a non-profit association formed in 1974 that promotes the advancement of science, research and clinical management in the field of

atherosclerosis. The AAS is internationally recognised and hosted the 2012 International Symposium on Atherosclerosis in Sydney. AAS members have significant international profiles in both the clinical and scientific spheres.

Our > 130 members are researchers in the field of atherosclerosis and cardiovascular disease.



FHAN. The AAS also incorporates the Familial Hypercholesterolaemia Australasia Network (FHAN). Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. The FHAN runs the National FH Registry Database, and drives multiple studies in FH across more than 10 countries globally, including Australia, Hong Kong, Taiwan,

Brazil South Africa *everyone deserves a better chance*

Malaysia and others. The FHAN Board is represented by the key lipid clinicians and researchers in Australia and is headed by Professor Gerald F Watts. <http://www.athero.org.au>



The Australian Vascular Biology Society (AVBS) is an organization active throughout Australia and New Zealand which aims to foster research communication by scientists and clinicians from a broad range of disciplines but with a unifying interest in biology of the cardiovascular system.

The Society holds annual scientific meetings and our 90 members contribute to a series of international vascular biology meetings as part of a group of similar organizations in Europe, Japan and North America. Students are encouraged to join the Society and attend meetings where there are attractive prizes for student presentations.

The main areas of interest include atherosclerosis, inflammation, thrombosis, angiogenesis, endothelial function, hypertension and diabetes. <http://www.avbs.org>

2020 JOINT ANNUAL SCIENTIFIC MEETING

The 2020 Annual Scientific Meetings will run as a joint meeting between all three societies. It will be held at RACV Club Melbourne, from December 1-4 2020. Attendance is again expected to be strong with around 200 - 250 clinicians and scientists present.

The 2020 Joint Annual Scientific Meeting will explore several exciting subjects. The meeting will officially run from 1 Dec to 4 Dec 2020 with the ASM Awards Dinner held on Thursday 3 December.

Presentations and abstracts will focus on the following areas:

- Diet & Lifestyle & CVD
- Inflammation & CVD
- Platelets and Atherothrombosis
- Immune interactions with the vasculature
- Lipids & Atherosclerosis
- Vascular and lymphatic development
- Cellular mechanisms of CVD
- Vascular Niches
- Clinical Insights into CVD

Special invited guest lecturers will again feature on this highly esteemed program, including these invited Keynote Speakers:

International speaker - AAS



Nicholas Leeper, Stanford, Associate Professor of Surgery (Vascular Surgery) and of Medicine (Cardiovascular Medicine)

The Leeper laboratory studies the vascular biology of atherosclerosis and aneurysm disease. They are interested in the molecular mechanisms that mediate vascular disease, and developing new translational therapies directed against them. Their group uses a combination of hypothesis-free genetic approaches, favoring the concept that insights generated in this manner are likely to have relevance to human disease. Currently, the Leeper lab's major focus is on the chromosome 9p21 locus, which is widely recognized as the most important heritable cardiovascular locus identified through genome-wide association studies (GWAS). They seek to fully explain how this locus - which affects over 20% of the population - potentiates coronary disease, stroke and aneurysms, and does so independently of all classical risk factors. The Leeper group pursues the goal of true 'bench-to-bedside' translation, and includes a basic genetics, molecular biology and mouse model team, as well as a translational Vascular Medicine team which performs early-phase clinical research. Ultimately, they seek to develop a platform of new therapies directed against atherosclerosis, which is now the leading killer worldwide.

Read more [HERE](#)

International speaker - AVBS



Professor Anne Eichmann, Yale Cardiovascular Research Center.

Ensign Professor of Medicine (Cardiology) and Professor of Cellular and Molecular Physiology.

Anne's laboratory studies vascular and lymphatic development, with particular emphasis on mechanisms that direct patterning and guidance. Specialized endothelial cells (EC) called tip cells located at the extremities of growing capillary sprouts mediate guided vascular patterning. Tip cells exhibit characteristic features, including extension of filopodia that explore the tip cell environment, lack of a lumen and a slow proliferation rate. EC behind tip cells, termed stalk cells form the capillary lumen and proliferate.

Read more about Anne's work [HERE](#).

RD Wright invited Lecturer: HBPRCA

Professor Martha Gulati, MD, MS, FACC, FAHA, Division Chief, Cardiology, College of Medicine, Phoenix Arizona



As division chief of Cardiology for the UA College of Medicine – Phoenix and physician executive director for the Banner – University Medicine Heart Institute, Dr. Martha Gulati leads educational activities in cardiovascular sciences for medical students, residents and fellows at the college and Banner Health. She also heads clinical heart care as the director of the Cardiovascular Institute at Banner.

She completed medical school at the University of Toronto, Canada; her internship, residency and cardiology fellowship at the University of Chicago; is a fellow of the American College of Cardiology and the American Heart Association; and is board-certified in cardiovascular disease.

Dr. Gulati is passionate about the study of women and heart disease, as well as about its prevention. As the principal investigator of the St. James Women Take Heart Project, a study examining cardiac risk factors in women, she's helped to set new standards for women's fitness levels and heart rate response to exercise in women. In addition, she is a co-investigator on the Women Ischemic Syndrome Evaluation (WISE); she previously served as a co-investigator on the Women's Health Initiative (WHI); is a member of numerous advisory boards and societies, including the American Heart Association and the American College of Cardiology; and has published articles in peer-reviewed publications, such as The New England Journal of Medicine, Circulation and Journal of the American Medical Association (JAMA). Her

exceptional commitment to this prevalent health issue has also won her numerous awards and distinctions.

Prior to her time with the UA College of Medicine – Phoenix, Dr. Gulati served as an associate professor of Medicine and Clinical Public Health in the Division of Cardiology at the Ohio State University, where she was the Sarah Ross Soter Chair in Women's Cardiovascular Health and the section director for Women's Cardiovascular Health and Preventive Cardiology.

Read more [HERE](#)

Colin I Johnston invited Lecturer: HBPRCA

Associate Professor, Elizabeth Lambert, Swinburne University of Technology



A/Prof Elisabeth Lambert joined the Faculty of Health, Art and Design in February 2017. She previously worked at the Baker Heart and Diabetes Institute for 18 years. Elisabeth's research program focusses on the sympathetic nervous function in a number of important clinical conditions such as hypertension, obesity, metabolic syndrome, type-2 diabetes and chronic kidney disease. Most of her efforts have focused on the understanding of the role played by the sympathetic nervous system in the development of metabolic abnormalities and organ damage with a view of implementing novel treatment modalities in order to decrease cardiovascular risk.

Recent major achievements of her group include:

- Refinement and application of techniques for studying single-unit muscle sympathetic nerve activity in the context of hypertension and obesity as well as anxiety/affective disorders.
- Identifying a defect in the noradrenaline transporter, a key protein of the sympathetic nerve terminals, in the pathology of postural tachycardia syndrome.
- Demonstration that young normotensive individuals with excess adiposity have subclinical organ damage (cardiac, renal and endothelial) and that the degree of organ dysfunction is directly related to the degree of sympathetic activation.
- Demonstration that the hormone ghrelin was involved in modulating sympathetic nervous activity and stress response.
- Demonstration of the link between sympathetic activity and endothelial dysfunction in women with dyslipidemia.
- Elisabeth Lambert has published over 150 papers and has been a chief investigator on 10 NHMRC grants.

Read more about her work [HERE](#)

Austin Doyle invited Lecturer: HBPRCA

Professor Suzanne Cory, BSc Melb PhD Cantab Hon DSc Syd Hon DSc Oxon FAA FRS, Laboratory Head, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research



Professor Cory's laboratory investigates the role of different genetic changes in the development of leukemia and lymphoma. They also examine how these changes influence the response of cancer cells to chemotherapy.

They study leukaemogenesis, with a particular focus on MYC, a potent oncoprotein, and the BCL-2 family of proteins, which control cell life and death. They pioneered transgenic models of human Burkitt's lymphoma, which is provoked by MYC, and follicular lymphoma, provoked by BCL-2. They collaborated in the development of agents called BH3 mimetics, which block the action of specific pro-survival Bcl-2 family proteins. Using their models, they have shown that a combination of a BH3 mimetic with low dose chemotherapy is highly efficacious *in vivo* against aggressive lymphomas that express high levels of BCL-2 and MYC. They are now testing BH3 mimetic combination therapy to treat acute myeloid leukaemia (AML).

The lab is currently investigating the role of MNT, a MYC-related protein, in lymphocytes and lymphoid tumours.

Read more [HERE](#)

National Invited Speakers:

Erica Fletcher, University of Melbourne



Prof Erica Fletcher is a Professor of the Department of Anatomy and Neuroscience and has over 15 years' experience in ophthalmological research. She is a clinically trained optometrist who holds both MSc and PhD degrees, which was completed in 1996 investigating the neurochemical changes that occur in an animal model of retinal degeneration.

Prof Fletcher's postdoctoral training was undertaken with Prof. Dr. Heinz Wässle, at the Max-Planck Institute for Brain Research in Frankfurt, Germany funded by an NHM&MRC CJ Martin Award. Prof Fletcher has been a tenured academic at The University of Melbourne since 2000. A central focus of Prof Fletcher's work has been the translation of her work to address clinically significant questions and to aid in the development of better treatments for retinal disease. Prof Fletcher has received considerable research funding primarily from the NH&MRC and also a number of international funding agencies (e.g., Health Research Council, New Zealand, American Health Assistance Foundation), published widely in a range of high impact journals, whilst maintaining a teaching load and mentoring of research personnel. In addition Prof Fletcher serves on a number of editorial boards, provides leadership

within optometry by serving on boards of management, as well as serving the research community through NHMRC grant review panels. In recognition of her excellence in vision research, Prof Fletcher was awarded the 2019 H Barry Collin Research Medal, the 2016 Glen Fry Award and the 2006 Irvin M and Beatrice Borish Award from the American Academy of Optometry. Prof Fletcher's research interests remain primarily focused on understanding the causes of retinal diseases.

Rebecca Ritchie, Monash MIPS, Melbourne



Professor Ritchie is currently an NHMRC Senior Research Fellow and Head of the Heart Failure Laboratory at the Baker Heart and Diabetes Institute.

A graduate of the Dept of Medicine (Cardiology) at the University of Adelaide under the supervision of Professor John Horowitz, Professor Ritchie's PhD focused on predictors of myocardial function in vivo in patients with coronary heart disease, including development of the first quantitative model of the force-interval relationship in human myocardium. Her postdoctoral training (with Prof James Marsh in the Program of Molecular and Cellular Cardiology at Wayne State University

1995-1997, USA) and the Florey (with Prof Greg Dusting, 1997-2002) led to her recruitment to the Baker (from late 2002).

Professor Ritchie leads a dynamic, internationally-recognised research program identifying new strategies to treat heart failure, particularly secondary to diabetes and myocardial infarction. Her research achievements to date have enabled her to identify potential new treatment strategies, both pharmacological and gene delivery-based, for arresting the progression of heart failure in preclinical models of human disease. As heart failure is a major cause of death worldwide for which there is no effective treatment, her efforts to identify new drug strategies for delaying or arresting its progression address an urgent, unmet clinical need.

Stephen Nicholls, Monash Heart



Professor Stephen Nicholls is the Director of Monash Heart and Professor of Cardiology at Monash University. He will be the Director of the Victorian Heart Hospital. He completed his cardiology training at John Hunter Hospital and PhD at the University of Adelaide, prior to holding a postdoctoral fellowship and faculty appointment at the Cleveland Clinic. He returned to Australia to serve as the inaugural Deputy Director and Heart Health Theme Leader at the South Australian Health and Medical Research Institute. His research interests focus on the role of metabolic risk factors and imaging in atherosclerosis,

with work spanning from early discovery to leadership of large clinical trials. He is Chair of the (i) Australian Atherosclerosis Society Clinical Council, (ii) Scientific Committee of the Australia and New Zealand Alliance for Cardiovascular Trials, (iii) Asia Pacific Cardiometabolic Consortium and (iv) Future Leader Fellowship committee of the National Heart Foundation, Secretary of the Cardiac Society of Australia and New Zealand, Fellow of the Australian Academy of Health and Medical Sciences and founding board member of the Australian Cardiovascular Alliance.

Ben Hogan, Peter MacCallum Centre



The Hogan lab investigates the lymphatic vasculature and the blood brain barrier, which play important roles in metastasis.

Ben Hogan completed his PhD in developmental biology at the Ludwig Institute for Cancer Research in 2005.

Following a year as a Cancer Council Victoria Fellow, he moved to the Hubrecht Institute for Stem Cell and Developmental Biology (Netherlands) to study the vasculature. This work was supported by an EMBO fellowship and an NHMRC CJ Martin Fellowship. During this time, he uncovered the role of *Ccbe1* in lymphangiogenesis and was part of a team that characterised CCBE1 mutations in generalized

lymphoedema in humans. This work was awarded the Postdoctoral Investigators Award from the NARF of the NHMRC in 2009.

Ben founded his own research team at the Institute for Molecular Bioscience, University of Queensland in 2010. Work from his group has since led to discovery of a number of genes essential for angiogenesis and lymphangiogenesis, characterization of molecular mechanisms controlling the CCBE1/VEGFC/VEGFR3 signaling axis and description of new cellular processes involved in vessel formation in live tissues. During his time in QLD, he was supported by an ARC Future Fellowship, an NHMRC/Heart Foundation Career Development Fellowship and received the Emerging Leader Award of the ANZSCDB (2016).

His group relocated to the Peter mac and the University of Melbourne in 2019.

Professor Hogan is an NHMRC Senior Research Fellow and his work is currently funded by grants from the NHMRC, ARC and Bright Focus Foundation (USA).

Professor Wally Thomas, University of Queensland




Walter (Wally) Thomas is the Acting Director of the University of Queensland Diamantina Institute, on secondment from his position as the Head of the UQ School of Biomedical Sciences. The Diamantina Institute, based at the Princess Alexandra Hospital in Brisbane, is made up of over 200 researchers, clinical researchers, students and support staff.

Professor Thomas' current research interests include the human cardiovascular system, and in particular the renin-angiotensin system and structure-function signaling in G protein-coupled receptors with specific interest in the link to growth factor receptors and cellular growth.

After receiving his PhD from the University of Queensland, Professor Thomas undertook postdoctoral research in the United States and Melbourne, Australia, supported by Fellowships from the National Health and Medical Research Council of Australia. He relocated to Brisbane in 2008 to take up a position as Professor of General Physiology and became Head of the School of Biomedical Sciences in 2009. He also holds an Affiliate Professor position with the Queensland Brain Institute.

Helena Qin, Baker Institute



Dr Chengxue (Helena) Qin is a Baker Fellow and Group Leader in at Baker Heart and Diabetes Institute, with adjunct appointments (Monash Institute of Pharmaceutical Science and Univ Melb).

A prominent early-mid career scientist. Qin has extensive experience in design and evaluation of novel drugs in relevant preclinical models of cardiovascular disease (CVD). Her translational research continues to develop novel strategies to treat various CVD and diabetic complications. Dr Qin was awarded her PhD in Oct 2010 in

the Faculty of Medicine (University of Melbourne). Her unique dual PhD training in CVD pharmacology and medicinal chemistry encompassed design, synthesis and profiling of an array of novel flavonol derivatives for treatment of heart attack (this group of compounds is completing phase-II clinical trial).

Her current research focuses on formyl peptide receptors, a group of GPCR involved in the regulation and resolution of inflammation. Dr Qin provided the first evidence that selectively engaging beneficial pathways at this receptor has significant therapeutic potential. Her group is developing novel drugs on this patented technology, in several therapeutic areas. Dr Qin's achievements have also been recognised by numerous highly prestigious awards including BPS/ASCEPT Outstanding Young Investigator Award (2015); CSANZ Ralph Reader Prize (Basic Science, 2016), Best Oral ECS presentation at ISHR (2017) and Baker Institute Fellow (2018–2022).

Michael De Silva, La Trobe University



Dr Michael De Silva completed his PhD in 2011 in the Department of Pharmacology at Monash University. In 2012, he was awarded an NHMRC CJ Martin Early Career Fellowship to conduct postdoctoral research at the University of Iowa (USA). There he gained expertise in the study of the cerebral microcirculation. In 2015, he returned to Australia and joined the Vascular Biology and Immunopharmacology Group (VBIG) headed by Professor's Chris Sobey and Grant Drummond.

Michael has published a number of papers in prestigious journals including Hypertension, Stroke and The British Journal of Pharmacology. He has also received recognition for his work including awards from the American Heart Association, American Physiological Society and the Australian Foundation for High Blood Pressure Research.

His current research interests include examining the effect of cardiovascular diseases (such as stroke and hypertension) on neurological outcomes and the regulation of cerebral microvascular function

James Hudson, QIMR, Brisbane



Dr James Hudson is the Group Leader for the Muscle Tissue Engineering Lab at the School of Biomedical Sciences at The University of Queensland. Dr Hudson completed a double major in Chemical and Biological Engineering in 2006 and subsequently completed his PhD on cardiac tissue engineering at The University of Queensland in 2011. Dr Hudson was then awarded a German Cardiology Society postdoctoral fellowship for training under the guidance of Prof Wolfram-Hubertus Zimmermann in Germany, one of the world's most prominent cardiac tissue engineering

researchers. Dr Hudson returned to Australia in 2013 on a NHMRC ECF and has recently received has recently been awarded an NHMRC CDF and National Heart Foundation Future Leaders Fellowship (2017-2020) for which he won the Paul Korner award for the top ranked national application. Dr Hudson also recently received the Centenary Institute Medical Innovation Award (2017) for his research program. Over his career Dr Hudson's work has focussed on the generation of human cardiomyocytes from pluripotent stem cells and the generation and use of human cardiac organoids for regenerative medicine and therapeutic target discovery applications.

Awards

As in previous years a number of awards will be presented including:

➤ **Student oral and poster presentations for all 3 societies**

Each winning oral presentation received \$1000 and a certificate, each winning poster presentation receives a certificate and \$500. These awards for all three societies are eligible for named sponsorship this year.

➤ **Early Career oral and poster presentations**

Each winning oral presentation received \$1000 and a certificate, each winning poster presentation receives a certificate and \$500. These awards for all three societies are eligible for named sponsorship this year.

Additional awards for HBPRCA:

➤ **Jaye Chin-Dusting award**

Prof Jaye Chin-Dusting was the second woman to be elected as the president of the HBPRCA (2011-2016). As a founder of the Australian Cardiovascular Alliance, Prof Chin-Dusting was deeply concerned with the funding available for cardiovascular disease, which affects particularly those in the early- and mid-stages of their career. During her presidency of the HBPRCA, she also established the young investigator subcommittee of the HBPRCA, to improve training, networking and opportunities for early and mid-career high blood

pressure researchers.

The highest ranked abstract for which the first author is a mid-career scientist (between 5-20 years post-PhD) will receive the Jaye Chin-Dusting Mid-career Scientist in High Blood Pressure Research Award. Only current HBPRCA members are eligible.

The awardee will be announced at the award ceremony (12pm Wed), where this person will receive a certificate and a **\$250 prize**.

➤ **Judith Whitworth award**

Prof Judith Whitworth was the first woman to be elected as the president of the HBPRCA (1999-2001). Throughout her career, Prof Whitworth not only contributed to a major way to high blood pressure research herself, and in particular to the mechanisms involved in steroid-related hypertension, but broke numerous barriers and paved a path for women in research, clinical practice and policy making.

The highest ranked abstract for which the first named author is a woman will receive the Judith Whitworth Women in High Blood Pressure Research Award. Only current HBPRCA members are eligible.

The awardee will be announced at the award ceremony (12pm Wed), where this person will receive a certificate and a **\$250 prize**.

➤ **Robert Vandongen award**

This prize is awarded to the highest scoring abstract from Western Australia, and receives a certificate **and \$500**

➤ **Paul Korner Medal**

Prof Paul Korner was one of the founders and a former president of the HBPRCA (1987-1989). He devoted a large part of his career to researching the causes of essential hypertension, with a special focus on underlying neural and cardiovascular mechanisms.

A senior scientist (>20 years post-PhD) who is an active researcher and has made a significant contribution to high blood pressure and the HBPRCA will receive the Paul Korner Senior Scientist in High Blood Pressure Research Medal.

Only current HBPRCA members who are attending the ASM are eligible (attendance may be excused under certain circumstances).

A one-page nomination by a HBPRCA member must be received by 31 October of each year outlining the contributions to high blood pressure research and the HBPRCA, and to mentoring of basic or clinical researchers in high blood pressure. Self-nominations will not be accepted. A sub-committee of 3-5 members of the HBPRCA executive committee will select the most suitable nominee each year. **An engraved medal and a prize of \$1000 will be awarded.**

➤ **BHS and AHA Awards**

Each year the HBPRCA supports the travel and accommodation for the winner of both the student and ECR Oral awards to attend either the BIHS or the AHA meeting in the following year, to the amount of \$3000. Likewise, the BIHS and AHA have a reciprocal agreement where their winning presenters attend HBPRCA each year.

Additional awards for AVBS:

- AVBS Achievement and Career Development Award. This Award is judged by the AVBS and presented annually.

The organizing committee is led by the current Presidents and Program Secretaries from each society:

| | President | Program Secretaries |
|---------------|------------------|-----------------------------------|
| HBPRCA | Markus Schlaich | Francine Marques & Brad Broughton |
| AAS | Peter Psaltis | Joanne Tan & Blake Cochran |
| AVBS | Natasha Harvey | Connie Wong |

2020 ASM PROGRAM OUTLINE

| | |
|----------------------|--|
| Tuesday December 1 | Joint New Investigator / ECR workshop including AAS SCOLAR Program |
| | Opening Plenary / Keynote speaker |
| Wednesday December 2 | International Speakers' plenaries, awards finalists |
| | AGMs |
| Thursday December 3 | Fun run / walk |
| | Oral Free Communications |
| | Awards presentations and Conference Dinner |
| Friday December 4 | Oral presentations including guest lecturers |

2020 ASM AWARDS DINNER

The 2020 Joint Annual Scientific Meeting Awards Dinner will be held on 3 Dec 2020 at RACV Club. As dinner tickets will be included in this year's delegate registration fees, it is expected that ALL delegates will also attend the dinner event.

During the evening, the many awards will be formally presented by each of the three societies to recognise the outstanding abstract submissions for both poster and oral presentations.

The Societies thank you for your continued commitment to this meeting, and look forward to seeing you in Melbourne!

Prof. Markus Schlaich
President HBPRCA

Prof. Peter Psaltis
President AAS

Prof. Natasha Harvey
President AVBS

Registration will open on May 1st please save the date in your diary!